 Non-alcoholic fatty liver disease, an AFLD, is a common condition affecting up to 25% of the global population. NAFLD can progress to a more serious form known as non-alcoholic steatohepatitis, NASH, which increases the risk of developing cirrhosis and liver cancer. Research suggests that inflammation plays a key role in the progression of NASH to cirrhosis and liver cancer. Additionally, the gut microbiome may play a role in the development of these diseases. This paper reviews the current evidence-linking inflammation, the gut microbiome, and liver cancer. This article was authored by Aveline Rodriguez-Lara, Ascension Rueda Robles, Maria Jose Sayez-Lara, and others.